Zhe Hou, MD
Dermatology · Brea, CANPI 1760800973
Payments from drug & device makers
Across 358 payments — averaging $356.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$54K
- Pfizer$32K
- Regeneron Healthcare Solutions, Inc.$31K
- Sanofi$7K
- AbbVie$1K
- LEO Pharma Inc.$526
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,3083%
- Speaking & faculty fees$33,66279%
- Travel & lodging$7082%
- Food & beverage$6,88716%
- Education$2771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 34 | $53,501 |
| Pfizer | 39 | $32,054 |
| Regeneron Healthcare Solutions, Inc. | 39 | $31,012 |
| Sanofi | 65 | $6,914 |
| AbbVie(2 entities) | 57 | $1,097 |
| LEO Pharma Inc. | 38 | $526 |
| Almirall LLC | 1 | $400 |
| Galderma Laboratories, L.p. | 18 | $363 |
| Johnson & Johnson | 8 | $263 |
| Novartis | 13 | $235 |
| Dermavant Sciences, Inc. | 3 | $214 |
| Amgen | 8 | $206 |
| Lilly USA, LLC | 5 | $163 |
| Sun Pharmaceutical Industries Inc. | 6 | $133 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $111 |
| Biofrontera Inc. | 3 | $71 |
| Arcutis Biotherapeutics, Inc. | 4 | $66 |
| Dermira, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| UCB, Inc. | 1 | $26 |
| Merz North America, Inc. | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Verrica Pharmaceuticals Inc. | 1 | $22 |
| Misonix Inc | 1 | $20 |
| VYNE Pharmaceuticals Inc. | 1 | $20 |
| Journey Medical Corporation | 1 | $18 |
| EPI Health, LLC | 1 | $15 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$127,576 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 37 | $139,444 |
| Halobetasol Propionate | 70 | $5,349 |
| Clobetasol Propionate | 78 | $2,426 |
| Betamethasone Dipropionate | 35 | $1,080 |
| Ketoconazole | 82 | $1,056 |
| Doxycycline Hyclate | 30 | $678 |
| Metronidazole | 12 | $425 |
| Triamcinolone Acetonide | 38 | $283 |
| Nystatin | 13 | $252 |
| Terbinafine Hcl | 15 | $220 |
| Mupirocin | 27 | $188 |
| Hydrocortisone | 34 | $118 |
| Cephalexin | 13 | $101 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Brea
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
- Paul WallaceBeverly Hills$7.1M
- April ArmstrongLos Angeles$6.2M
- David RayhanHuntington Beach$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.